Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Four Week, Dose Escalating Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Study of CTA018 Injection in Subjects With Stage 5 Chronic Kidney Disease With Secondary Hyperparathyroidism on Hemodialysis

NCT00742716 is registered in ClinicalTrials.gov with OPKO IP Holdings II, Inc. as lead sponsor.

NCT NCT00742716
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00742716 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Four Week, Dose Escalating Pharmacokinetic, Pharmacodynamic, Efficacy and Safety Study of CTA018 Injection in Subjects With Stage 5 Chronic Kidney Disease With Secondary Hyperparathyroidism on Hemodialysis
Lead sponsor
OPKO IP Holdings II, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2008
Completion date
June 30, 2010
Enrollment
41 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease, chronic renal failure, chronic renal insufficiency, secondary hyperparathyroidism